2026-06-14T03:52:13Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/168552024-09-21T12:19:11Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Gimeno, Juan R author Olivotto, Iacopo author Rodríguez, Ana Isabel author Ho, Carolyn Y author Fernández, Adrián author Quiroga, Alejandro author Espinosa, Mari Angeles author Gómez-González, Cristina author Robledo, María author Tojal-Sierra, Lucas author Day, Sharlene M author Owens, Anjali author Barriales-Villa, Roberto author Larrañaga, Jose María author Rodríguez-Palomares, Jose author González-Del-Hoyo, Maribel author Piqueras-Flores, Jesús author Reza, Nosheen author Chumakova, Olga author Ashley, Euan A author Parikh, Victoria author Wheeler, Matthew author Jacoby, Daniel author Pereira, Alexandre C author Saberi, Sara author Helms, Adam S author Villacorta, Eduardo author Gallego-Delgado, María author de Castro, Daniel author Domínguez, Fernando author Ripoll-Vera, Tomás author Zorio-Grima, Esther author Sánchez-Martínez, José Carlos author García-Álvarez, Ana author Arbelo, Elena author Mogollón, María Victoria author Fuentes-Cañamero, María Eugenia author Grande, Elias author Peña, Carlos author Monserrat, Lorenzo author Lakdawala, Neal K author 2022-08 AIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality. ESC Heart Fail. 2022 Aug;9(4):2189-2198. 10.1002/ehf2.13964 2055-5822 ESC heart failure 36255281 http://hdl.handle.net/20.500.12105/16855 Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.